Overview

A Study of the Safety and Tolerability of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis

Status:
Completed
Trial end date:
2018-05-30
Target enrollment:
Participant gender:
Summary
To assess the long-term safety and tolerability of ACP-103 in subjects with Parkinson's disease psychosis.
Phase:
Phase 3
Details
Lead Sponsor:
ACADIA Pharmaceuticals Inc.
Treatments:
Pimavanserin